SALT LAKE CITY--(BUSINESS WIRE)-- BSD Medical Corporation (NASDAQ: BSDM) (the “Company” or “BSD”) announced today that the MicroThermX® Microwave Ablation System (“MicroThermX®”) was featured at the Company’s exhibition booth at the 36th annual scientific meeting of the Society of Interventional Radiology (“SIR”), which was held in Chicago, Ill., March 26 to March 31, 2011. The SIR meeting is the largest and most comprehensive meeting in the US for minimally invasive interventional radiology/oncology products. Nearly 5,300 physicians, scientists and health professionals from around the world attended the meeting. BSD sponsored a hospitality suite during the show that was attended by key opinion leaders, a number of interventional oncologists and physicians experienced in using the MicroThermX® system.
"The SIR meeting was used to increase the profile of the Company’s microwave ablation products and to further develop the Company’s association with international key opinion leaders,” stated Steven Smith, VP for Marketing, Sales, and Business Development for BSD. "All of the US MicroThermX® distributors selected by BSD attended the show and hospitality suite and accompanied customers to the booth to preview the innovative design of the MicroThermX®. Our booth was also visited by a number of international distributors. We were pleased at the significant number of interventional oncologists who scheduled clinical evaluations of the MicroThermX® during and following the show.”
Interventional oncology is a growing specialty area of interventional radiology that is focused on the delivery of cancer treatments, including ablation therapy, that directly targets tumors without significant side effects or damage to nearby normal tissue. The SIR scientific program highlighted the rapidly growing field of interventional oncology. There were nearly 400 scientific presentations and 150 posters covering the latest developments in the field. Approximately 40% of these presentations focused on the advantages of interventional oncology cancer treatments, including ablation, as treatment options that provide less risk, less pain and less recovery time than open surgery. The potential global market for ablation treatments is expected to reach $2.3 billion.
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue and has received marketing clearance from the US FDA. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.
Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.
BSD Medical Corporation
Dennis Gauger, 801-972-5555
KEYWORDS: United States North America Illinois Utah
INDUSTRY KEYWORDS: Health Hospitals Medical Devices Oncology Radiology FDA General Health